Abstract: Systems for predicting a drug delivery profile as described herein include at least one drug pump and/or a controllable valve that produce a drug flow and dispense at least a first drug. The system also includes at least one carrier fluid pump and/or another controllable valve that produces a carrier fluid flow, a flow junction structure configured to receive the drug flow and the carrier fluid flow to produce a mixed flow, and a fluid path for carrying the mixed flow between the flow junction structure and a delivery point. The system further includes a processing device configured to predict the drug delivery profile at the delivery point based on determining a predicted time variation of drug concentration at the delivery point using at least a model of the mixed flow. The model includes a plurality of parameters related to propagation of the mixed flow through the fluid path.
Type:
Grant
Filed:
November 20, 2012
Date of Patent:
September 19, 2017
Assignees:
The General Hospital Corporation, Steward St. Elizabeth's Medical Center of Boston, Inc.
Inventors:
Robert A. Peterfreund, Michael Parker, Nathaniel M. Sims, Mark A. Lovich, Harold J. DeMonaco
Abstract: In accordance with the present invention, EC progenitors can be used in a method for regulating angiogenesis, i.e., enhancing or inhibiting blood vessel formation, in a selected patient and in some preferred embodiments for targeting specific locations. For example, the EC progenitors can be used to enhance angiogenesis or to deliver an angiogenesis modulator, e.g. anti- or pro-angiogenic agents, respectively to sites of pathologic or utilitarian angiogenesis. Additionally, in another embodiment, EC progenitors can be used to induce reendothelialization of an injured blood vessel, and thus reduce restenosis by indirectly inhibiting smooth muscle cell proliferation.
Type:
Application
Filed:
November 21, 2011
Publication date:
September 19, 2013
Applicant:
Steward St. Elizabeth's Medical Center of Boston, Inc.
Abstract: In accordance with the present invention, EC progenitors can be used in a method for regulating angiogenesis, i.e., enhancing or inhibiting blood vessel formation, in a selected patient and in some preferred embodiments for targeting specific locations. For example, the EC progenitors can be used to enhance angiogenesis or to deliver an angiogenesis modulator, e.g. anti- or pro-angiogenic agents, respectively to sites of pathologic or utilitarian angiogenesis. Additionally, in another embodiment, EC progenitors can be used to induce reendothelialization of an injured blood vessel, and thus reduce restenosis by indirectly inhibiting smooth muscle cell proliferation.
Type:
Grant
Filed:
March 17, 2003
Date of Patent:
December 13, 2011
Assignee:
Steward St. Elizabeth's Medical Center of Boston, Inc.
Inventors:
Jeffrey M. Isner, Linda Isner, legal representative, Takayuki Asahara, Douglas W. Losordo